Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Galena Biopharma, Inc. (GALE) Written Up In The Motley Fool

|Includes: SELLAS Life Sciences Group, Inc. (SLS)

The Motley Fool's recent evaluation of Galena Biopharma (dtg.fm/Yrd6) left little doubt as to the company's potential, focusing on their lead product, Neuvax, for its dramatic results in cancer fighting trials, but also indicating the significant possibilities for the company's cancer pain medication Abstral. Acknowledging that the company was still in the development stage, the article focused on Galena's future revenue opportunities based on Abstral and Neuvax, pointing out how smart investors know "that the key to winning hinges on having a good take on where things are headed rather than where they are now." Specifically, the article emphasized that whether Galena is poised for its big break in the not-too-distant future depends primarily on the prospects for these two products.

Key points:

•Galena purchased the rights to Abstral, a cancer pain medication, in March, and the drug already has U.S. regulatory approval, though the drug hasn't launched in the American market yet.

•Abstral is a fast-acting drug for reducing sudden pain suffered by cancer patients. Such breakthrough pain affects 40% to 80% of all cancer patients.

•Galena plans to proceed with Abstral commercialization in the fourth quarter of 2013.

•The U.S. market for drugs similar to Abstral totaled approximately $400 million in 2012.

•Galena's lead product, Neuvax, is designed to attack minimal residual disease that remains in cancer patients, representing a market of 20,000 patients in the U.S. alone, and the drug is currently in a late-stage clinical study targeting breast cancer.

•The article makes it clear that, if results of the current Neuvax clinical study prove as successful as earlier studies, "Galena could have a winner", indicating that "In the phase 1/2 trials, breast cancer patients taking Neuvax experienced a recurrence rate of 5.6% compared with a 25.9% recurrence rate in the control arm - an improvement of more than 78%".

•Galena's results have attracted the attention of Teva Pharmaceuticals (NYSE: TEVA), which has already acquired the rights to market Neuvax in Israel, pending regulatory approval.

•Though still below 2010 highs, GALE shares are up significantly since January.

For additional information, visit GalenaBiopharma.com

Please see disclaimer on the MissionIR website

www.missionir.com/disclaimer.html